Baksheev V I, Kolomoets N M
Klin Med (Mosk). 2007;85(3):4-11.
Type 5 phosphodiesterase inhibitors (5-PDEI), which have been applied as the basic medication for erectile dysfunction, are now being studied in various areas of clinical medicine (pulmonology, cardiology, gastroenterology, gynecology etc.) This systematic literature review is dedicated to 5-PDEI, the state of the problem, the prospects of clinical application of sildenafil, and is based upon 450 literature sources from MEDLINE database (from 1954 to June 2006) and the Cochrane Collaboration database (from 1977 to March 2005) found by key words sildenafil, phosphodiesterase, and 5-PDEI. The issues of physiology and pathophysiology of 5-PDEI, the historical background of their creation, the appropriateness and efficacy of sildenafil in pulmonary arterial hypertension are considered in Part I of the review.
5型磷酸二酯酶抑制剂（5-PDEI）已被用作治疗勃起功能障碍的基本药物，目前正在临床医学的各个领域（肺病学、心脏病学、胃肠病学、妇科学等）进行研究。本系统文献综述致力于5-PDEI、问题现状、西地那非的临床应用前景，并基于从MEDLINE数据库（1954年至2006年6月）和Cochrane协作数据库（1977年至2005年3月）中通过关键词西地那非、磷酸二酯酶和5-PDEI找到的450篇文献来源。综述的第一部分考虑了5-PDEI的生理学和病理生理学问题、其产生的历史背景、西地那非在肺动脉高压中的适用性和疗效。
